|
Synonyms: AMG-162 | M05BX04 | Prolia® | Xgeva®
denosumab is an approved drug (FDA and EMA (2010))
Compound class:
Antibody
Comment: Denosumab suppresses the activity of RANK ligand (RANKL), which normally promotes bone removal and resorption, but which becomes over active in many bone loss diseases.
Denosumab is produced from CHO cells stably expressing recombinant antibody component proteins [1]. It was the first RANKL inhibitor to be approved by the FDA. Biosimilars: The FDA approved denosumab-bbdz (Jubbonti®, February 2024) and denosumab-bbdz (Wyost®, March 2024) as interchangeable biosimilars to the reference agent Prolia®. EMA approvals for Jubbonti® and Wyost® followed in May 2024. 
View more information in the IUPHAR Pharmacology Education Project: denosumab |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
